Our Corporate Patron
One Nucleus is delighted that AstraZeneca will continue its long-held relationship as Corporate Patron. Over the decade of support to date, AstraZeneca has provided a number of its staff as advisors, speakers and steering group members to help deliver strategic guidance to One Nucleus as one of the region’s key stakeholders. Highlighting AstraZeneca’s commitment to the partnership with One Nucleus, it is our pleasure to have Penny James, Chief Operating Officer BioPharmaceutical R&D as a Non-Executive Director. The breadth of this engagement means we have formed a strong and productive relationship with AstraZeneca, based on shared ambitions for the Cambridge and wider UK life sciences community. The shared ambitions for the region’s life science cluster to be the world-leading bioinnovation hub is key to both of our organisations. One Nucleus strives to enable knowledge sharing on the latest innovations in the scientific, business and investment aspects of the sector. AstraZeneca’s willingness to dedicate strategic resource to us, such as event speakers and updates, significantly enhances our delivery. Their engagement provides insight to the nascent companies, their founding entrepreneurs and investors, on how exceptional scientific innovation can be translated into patient benefit globally. This fits well with the collective aspirations of our cluster’s ecosystem; to create life changing technologies and products that have a global impact on lives. AstraZeneca’s role as a global leader and regional champion, in terms of science and societal impact has never been more evident as in their response to the COVID-19 pandemic. Leading the charge in development and supply of vaccines; their non-profit supply pledge to enable global access; local engagement in mentoring-style schemes; and strong practices on environment and diversity exemplify the aspirations of the cluster and One Nucleus’s desire to promote best practice. Tony Jones, CEO
14 | One Nucleus Annual Review & Directory 2021/2022
